Former Bionano Genomics Chief Medical Officer joins Nabsys at a pivotal moment as the Company expands commercialization of its electronic genome mapping platform Dr. Chaubey will lead medical and scientific affairs strategy as Nabsys works to expand global access to high-resolution structural variant analysis for cancer, constitutional, and cell and gene therapy applications PROVIDENCE, R.I. — Nabsys […]
Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation Highly Qualified, Independent and Accountable Board Has Taken Decisive Action to Advance Stockholders’ Best Interests Board Urges Stockholders to Vote “FOR” ONLY Seer’s Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif. — Seer, Inc. (Nasdaq: […]
Board Chair Maria Rankka has today notified the Board of Directors that she will step down as Board Chair and board member of BICO Group AB (publ) effective 31 July 2026. Board members Susanne Lithander and Johan Westman have also informed the Board that they will leave their Board assignments at the same time. The […]
Former Bionano Genomics Chief Medical Officer joins Nabsys at a pivotal moment as the Company expands commercialization of its electronic genome mapping platform Dr. Chaubey will lead medical and scientific affairs strategy as Nabsys works to expand global access to high-resolution structural variant analysis for cancer, constitutional, and cell and gene therapy applications PROVIDENCE, R.I. — Nabsys […]
Cambridge, UK – bit.bio, the Cambridge-based human cell programming company, has today announced the launch of two new cell culture media kits designed to make human cell-based research significantly more accessible and affordable for laboratories worldwide. Developed for use with bit.bio’s human iPSC-derived ioGlutamatergic Neurons and ioMicroglia, the easy-to-use media kits remove one of the major […]
Agreement expands Active Motif’s research genomics portfolio while supporting Arima’s strategic focus on its clinical diagnostics platform CARLSBAD, Calif. — Active Motif, a leading provider of epigenetics and multiomic solutions to mechanistic, translational, and clinical researchers, today announced an exclusive global commercial distribution agreement with Arima Genomics, a cancer diagnostics company built on leadership in […]
No Stockholder Action Required at This Time REDWOOD CITY, Calif. — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has received an unsolicited, non-binding proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class […]
AnalytiChem consolidates chemicals product expertise, innovation and heritage under one unified global brand AnalytiChem brings together Bernd Kraft, Chem-Lab and SCP Science under a unified global AnalytiChem product brand Eschborn, Germany — AnalytiChem, manufacturer of specialized chemicals, reagents, accredited standard, equipment and consumables, has announced that the brand transition of its chemical product ranges, currently […]
Agreement Part of Arima’s Long-Term Strategy to Focus on Core Diagnostic Platform and Tests CARLSBAD, Calif. — Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced a distribution partnership with Active Motif Incorporated, a leading provider of epigenetics and multiomic solutions to mechanistic, translational, and […]
Seer’s particle-based proteomics IP withstands challenges in both Europe and the United States REDWOOD CITY, Calif. — Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced two significant developments that reinforce the strength of the intellectual property portfolio protecting its proprietary nanoparticle protein enrichment technology. These milestones underscore Seer’s […]
Pay Invoice
Latest Blogs
-
EU Roadmap Provides Further Impetus for New Approach Methodologies
June 29, 2026 12:56 pm
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
-
Carterra Introduces Faster SPR
March 27, 2026 7:26 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
